Eupraxia Pharmaceuticals (NASDAQ:EPRX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) from a strong sell rating to a sell rating in a research report report published on Saturday,Wall Street Zen reports.

EPRX has been the subject of a number of other reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Eupraxia Pharmaceuticals in a report on Wednesday, July 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Friday, July 17th. Oppenheimer assumed coverage on shares of Eupraxia Pharmaceuticals in a research report on Thursday, June 25th. They set an “outperform” rating and a $17.00 price objective for the company. Finally, Stifel Nicolaus began coverage on shares of Eupraxia Pharmaceuticals in a research note on Thursday, May 21st. They issued a “buy” rating and a $25.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Eupraxia Pharmaceuticals Stock Performance

Shares of Eupraxia Pharmaceuticals stock opened at $8.07 on Friday. The company has a current ratio of 16.00, a quick ratio of 16.00 and a debt-to-equity ratio of 0.02. The business has a 50-day moving average price of $6.87 and a two-hundred day moving average price of $6.99. Eupraxia Pharmaceuticals has a 1-year low of $5.16 and a 1-year high of $9.32. The company has a market cap of $524.70 million, a P/E ratio of -7.91 and a beta of 1.07.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.02. As a group, analysts anticipate that Eupraxia Pharmaceuticals will post -0.85 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Persistent Asset Partners Ltd bought a new position in Eupraxia Pharmaceuticals in the second quarter worth approximately $25,000. AXQ Capital LP increased its holdings in shares of Eupraxia Pharmaceuticals by 34.2% during the second quarter. AXQ Capital LP now owns 21,150 shares of the company’s stock valued at $140,000 after acquiring an additional 5,390 shares in the last quarter. BlackRock Inc. bought a new stake in shares of Eupraxia Pharmaceuticals during the second quarter valued at approximately $40,000. Bank of America Corp DE raised its position in shares of Eupraxia Pharmaceuticals by 5.9% during the first quarter. Bank of America Corp DE now owns 268,221 shares of the company’s stock worth $1,942,000 after purchasing an additional 14,900 shares during the period. Finally, Royal Bank of Canada raised its position in shares of Eupraxia Pharmaceuticals by 33.2% during the first quarter. Royal Bank of Canada now owns 261,376 shares of the company’s stock worth $1,893,000 after purchasing an additional 65,099 shares during the period.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc (NASDAQ:EPRX) is a clinical-stage biotechnology company based in Canada. The company develops locally administered therapies intended to treat inflammatory, fibrotic and other diseases while limiting patients’ exposure to medication throughout the body.

Eupraxia’s development programs are built around its proprietary Diffusion Driven Drug Delivery (3D) platform. The technology is designed to provide controlled, sustained release of pharmaceutical compounds at targeted sites, potentially extending treatment effects and reducing systemic side effects.

The company’s lead product candidate, EP-104I, is an extended-release formulation of fluticasone propionate being developed for intra-articular administration in patients with osteoarthritis of the knee.